Achaogen Wins CARB-X Funding Award to Advance Development of LpxC Inhibitor Antibiotic to Fight Drug Resistant Infections
-- CARB-X funding highlights Achaogen’s innovative LpxC program and urgent need for gram-negative antibiotics -- -- Awarded $3.2 million over 12 months, and potentially up to a total award of $11.4 million -- SOUTH SAN FRANCISCO, Calif., July 25, 2017 ( …